Lomustine (CCNU)

DRUG2 trials

Sponsors

Pfizer, Karyopharm Therapeutics Inc

Conditions

GlioblastomaGlioblastoma Multiforme

Phase 1

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

TerminatedNCT04421378

Karyopharm Therapeutics IncGlioblastoma Multiforme

Start: 2020-06-08End: 2023-07-03Updated: 2024-12-16

Phase 3

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

CompletedNCT00068952

PfizerGlioblastoma

Start: 2003-08-31End: 2006-03-31Target: 118Updated: 2008-04-01

Related Papers

Abstract 6022: Synergistic anti-cancer effects of selinexor and bevacizumab in mouse xenograft models of glioblastoma

Cancer Research2022-06-151 citations

Abstract 6023: Selinexor synergizes with temozolomide in preclinical models of glioblastoma independent of MGMT promoter methylation

Cancer Research2022-06-15

Digital monitoring and assessments in patients with glioblastoma.

Journal of Clinical Oncology2022-06-01

CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA

Neuro-Oncology2021-11-02

Digital measurement of functional status of patients with glioblastoma.

Journal of Clinical Oncology2021-05-20

A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.

Journal of Clinical Oncology2021-05-20

CTNI-18. FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (rGBM)

Neuro-Oncology2020-11-011 citations

RTID-08. A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA (ndGBM OR rGBM)

Neuro-Oncology2020-11-01